Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunological pathomechanisms in vitiligo.

E H Kemp1, E A Waterman, A P Weetman

  • 1Division of Clinical Sciences, Northern General Hospital, University of Sheffield, Sheffield, S5 7AU, UK. e.h.kemp@sheffield.ac.uk

Expert Reviews in Molecular Medicine
|October 31, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An update on the pathogenesis of Hashimoto's thyroiditis.

Journal of endocrinological investigation·2020
Same author

Alemtuzumab-induced halo naevus-like hypopigmentation - new insights into secondary skin autoimmunity in response to an immune cell-depleting antibody.

Journal of the European Academy of Dermatology and Venereology : JEADV·2020
Same author

Association between the angiotensin-converting enzyme gene insertion/deletion polymorphism and susceptibility to systemic lupus erythematosus in an Indian population.

Scandinavian journal of rheumatology·2015
Same author

Tumour necrosis factor-α antagonists as therapies for vitiligo.

The British journal of dermatology·2015
Same author

The Pathogenesis of Hashimoto's Thyroiditis: Further Developments in our Understanding.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·2015
Same author

The CC genotype of the ERCC1 C118T single-nucleotide polymorphism impacts positively on the efficacy of narrowband ultraviolet B therapy for vitiligo.

The British journal of dermatology·2015

Vitiligo, a skin depigmentation disorder, may involve autoimmune responses. Research indicates the presence of autoantibodies and T cells targeting pigment cells in vitiligo patients, suggesting immune system involvement in disease development.

Area of Science:

  • Immunology
  • Dermatology
  • Autoimmunity

Background:

  • Vitiligo is a depigmenting skin disorder involving melanocyte loss.
  • Its exact cause is unknown, but immune system abnormalities are frequently observed.

Purpose of the Study:

  • To review and discuss the evidence supporting immunological pathomechanisms in vitiligo pathogenesis.
  • To explore the autoimmune component of vitiligo.

Main Methods:

  • Review of existing literature on vitiligo and immune responses.
  • Analysis of studies detecting autoantibodies and autoreactive T cells in vitiligo patients.
  • Examination of associations between vitiligo and other autoimmune diseases.

Main Results:

Related Experiment Videos

  • Circulating autoantibodies and autoreactive T cells targeting pigment cell antigens are detected in vitiligo patients.
  • Vitiligo frequently co-occurs with autoimmune conditions like Hashimoto's thyroiditis and type 1 diabetes.
  • Successful treatment with immunosuppressive therapies supports an immune role.

    • Conclusions:

    • Evidence strongly suggests that immune reactions play a significant role in the pathogenesis of vitiligo.
    • Vitiligo may have an autoimmune component, driven by immune responses against melanocytes.